Literature DB >> 29152511

Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?

Helen A Powell1, David R Baldwin2.   

Abstract

Entities:  

Year:  2017        PMID： 29152511      PMCID： PMC5673782          DOI： 10.21037/atm.2017.08.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Guidelines on the radical management of patients with lung cancer.

Authors:  Eric Lim; David Baldwin; Michael Beckles; John Duffy; James Entwisle; Corinne Faivre-Finn; Keith Kerr; Alistair Macfie; Jim McGuigan; Simon Padley; Sanjay Popat; Nicholas Screaton; Michael Snee; David Waller; Chris Warburton; Thida Win
Journal:  Thorax       Date:  2010-10       Impact factor: 9.139

3.  ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).

Authors:  A Brunelli; A Charloux; C T Bolliger; G Rocco; J-P Sculier; G Varela; M Licker; M K Ferguson; C Faivre-Finn; R M Huber; E M Clini; T Win; D De Ruysscher; L Goldman
Journal:  Eur Respir J       Date:  2009-07       Impact factor: 16.671

4.  Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment.

Authors:  Wendy Hopmans; Laura Zwaan; Suresh Senan; Ineke van der Wulp; Olga C Damman; Koen J Hartemink; Egbert F Smit; Danielle R M Timmermans
Journal:  Radiother Oncol       Date:  2015-05-30       Impact factor: 6.280

5.  Power imbalance prevents shared decision making.

Authors:  Natalie Joseph-Williams; Adrian Edwards; Glyn Elwyn
Journal:  BMJ       Date:  2014-05-14

6.  Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.

Authors:  N E Verstegen; J W A Oosterhuis; D A Palma; G Rodrigues; F J Lagerwaard; A van der Elst; R Mollema; W F van Tets; A Warner; J J A Joosten; M I Amir; C J A Haasbeek; E F Smit; B J Slotman; S Senan
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

7.  Patients' attitudes to risk in lung cancer surgery: A qualitative study.

Authors:  H A Powell; L L Jones; D R Baldwin; J P Duffy; R B Hubbard; A M Tod; L J Tata; J Solomon; M Bains
Journal:  Lung Cancer       Date:  2015-08-24       Impact factor: 5.705

8.  Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries.

Authors:  Emma L O'Dowd; Margreet Lüchtenborg; David R Baldwin; Tricia M McKeever; Helen A Powell; Henrik Møller; Erik Jakobsen; Richard B Hubbard
Journal:  Lung Cancer       Date:  2016-03-15       Impact factor: 5.705

9.  Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis.

Authors:  Subroto Paul; Paul C Lee; Jialin Mao; Abby J Isaacs; Art Sedrakyan
Journal:  BMJ       Date:  2016-07-08

10.  The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.

Authors:  M P Snee; L McParland; F Collinson; C M Lowe; A Striha; D R Baldwin; B Naidu; D Sebag-Montefiore; W M Gregory; J Bestall; J Hewison; S Hinsley; K Franks
Journal:  Pilot Feasibility Stud       Date:  2016-02-01
View more
  1 in total

1.  The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer.

Authors:  Brett Hauber; John R Penrod; David Gebben; Lina Musallam
Journal:  Patient Prefer Adherence       Date:  2020-10-30       Impact factor: 2.711
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.